Other · developed by United Therapeutics
GGTA1 KO Thymokidney is a porcine kidney carrying an intentional genomic alteration, transplanted together with a thymic tissue autograft, for xenotransplantation. It is studied in end-stage renal disease patients who need a kidney transplant.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07224763 | Phase 1/2 | ESRD (End-Stage Renal Disease) | Recruiting | UTHR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
ESRD (End-Stage Renal Disease)Kidney TransplantationXenotransplantation
Updated Nov 1, 2026. Something wrong or missing? Report it on the UTHR page.
See UTHR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
UTHR catalysts and pipeline →